Share Issue/Capital Change • Dec 3, 2025
Share Issue/Capital Change
Open in ViewerOpens in native device viewer
Inify Laboratories: Board announces updated timetable for settlement in proposed Private Placement and Repair Issue
STOCKHOLM - December 3, 2025 - The board of directors of Inify Laboratories AB
("Inify" or the "Company") announces its intention to postpone the last date of
payment in the Company's proposed share issues announced on November 12, 2025,
(the "Private Placement" and the "Repair Issue" respectively). The final payment
date is intended to be postponed to March 25, 2026, providing shareholders with
additional time to procure the necessary funds to participate in the Private
Placement and the Repair Issue.
The postponement of the last date of payment will also affect the expected final
date of delivery of new shares in the Private Placement and the Repair Issue.
The new shares in the Private Placement and the Repair Issue are expected to be
fully delivered to the participants in the Private Placement and Repair Issue by
March 30, 2026. Further, all the new shares allocated in the Private Placement
and the Repair Issue are expected to be tradable on Euronext Growth Oslo by
March 30, 2026.
For further information, please contact CEO, Fredrik Palm,
[email protected],or visit
https://www.inify.com (https://protect.checkpoint.com/v2/r02/___https://www.inify
.com___.YzJlOnNjaGpkdGFzOmM6bzo5MDBmMTZjMGY3NGQ5ZTU0NWU5NzM1MTk1ZGEyN2M2Njo3OjFjM
TM6YjE3M2Q4MTI2YmQxZjEyYzJmYWVhMzdlYWFiMTNiZGVlMjdkZjA1MjdlMTNjN2JlOTMyYmNkZDZmNz
ViNjhhMjpwOlQ6VA)
The future of diagnostics
Inify Laboratories offers diagnostics through specialised laboratory services in
histopathology, with a focus on streamlining patient pathways. The company
performs clinical diagnostics in prostate cancer and gastroenterology, providing
an integrated service that spans from early sample handling to final diagnosis.
The laboratory system is scalable both in handling large volumes of patient
samples and for replicating in new locations.
Quality and response times are optimised in every step - from logistics to
tissue preparation and diagnosis - using a fully digital, standardised and AI
-assisted workflow. The diagnosis is always performed by a pathologist and is
assisted by Inify's proprietary AI, proven to have world-leading precision in
clinical evaluations. The entire workflow is supported by a tailor-made system
that also enables development to include additional diagnostic areas.
Inify Laboratories is an international group headquartered in Solna, Sweden,
with local laboratories in Sweden and the UK. The company's share is listed on
Euronext Growth Oslo(https://live.euronext.com/en/product/equities/SE0017486103
-MERK (https://protect.checkpoint.com/v2/r02/___https://live.euronext.com/jsduwti
zhydjvznynjxdXJ556a9b*~*658
-RJWP___.YzJlOnNjaGpkdGFzOmM6bzo5MDBmMTZjMGY3NGQ5ZTU0NWU5NzM1MTk1ZGEyN2M2Njo3Ojc3
NWM6NjI5NGQxMjU2MWFmMzA4MTQzNTNmMGIyMzM3NGM5NGY2NjUxOTk0MzYwZDA3YTQ0ZGNjN2M3YjZlO
TE5NmJhMjpwOlQ6VA)) under the ticker
INIFY.(https://live.euronext.com/en/product/equities/SE0017486103
-MERK (https://protect.checkpoint.com/v2/r02/___https://live.euronext.com/jsduwti
zhydjvznynjxdXJ556a9b*~*658
-RJWP___.YzJlOnNjaGpkdGFzOmM6bzo5MDBmMTZjMGY3NGQ5ZTU0NWU5NzM1MTk1ZGEyN2M2Njo3Ojc3
NWM6NjI5NGQxMjU2MWFmMzA4MTQzNTNmMGIyMzM3NGM5NGY2NjUxOTk0MzYwZDA3YTQ0ZGNjN2M3YjZlO
TE5NmJhMjpwOlQ6VA))
This information is subject to the disclosure requirements pursuant to section 5
-12 the Norwegian Securities Trading Act.
Important information
The release, announcement or distribution of this press release may, in certain
jurisdictions, be subject to restrictions. The recipients of this press release
in jurisdictions where this press release has been published or distributed
shall inform themselves of and follow such restrictions. The recipient of this
press release is responsible for using this press release, and the information
contained herein, in accordance with applicable rules in each jurisdiction. The
information in this press release does not contain or constitute an offer to
acquire, subscribe or otherwise trade in shares, subscription rights or other
securities in the Company in any jurisdiction.
This press release does not identify or suggest, or purport to identify or
suggest, the risks (direct or indirect) that may be associated with an
investment in new shares. Any investment decision in connection with the Private
Placement and Repair Issue must be made on the basis of all publicly available
information relating to the Company and the Company's shares. Such information
has not been independently verified by SB1 Markets. The information contained in
this announcement is for background purposes only and does not purport to be
full or complete. No reliance may be placed for any purpose on the information
contained in this announcement or its accuracy or completeness. SB1 Markets is
acting for the Company in connection with the transaction and no one else and
will not be responsible to anyone other than the Company for providing the
protections afforded to its clients nor for giving advice in relation to the
transaction or any other matter referred to herein.
This press release does not constitute a recommendation concerning any
investor's option with respect to the Private Placement and Repair Issue. Each
investor or prospective investor should conduct his, her or its own
investigation, analysis and evaluation of the business and data described in
this announcement and publicly available information. The price and value of
securities can go down as well as up. Past performance is not a guide to future
performance.
The information contained in this press release is not intended for, and must
not be accessed by, or distributed or disseminated, directly or indirectly, in
whole or in part, to persons resident or physically present in the United States
of America (including its territories and possessions, any state of the United
States and the District of Columbia) (the "United States"), Australia, Canada,
Hong Kong, Japan, New Zealand, Singapore, South Africa, United Kingdom or any
other jurisdiction where such action is wholly or partially subject to legal
restrictions, or would require additional prospectuses, registration or other
measures than those required by Swedish law. The information in the press
release does not constitute any offer regarding subscription rights, paid
subscribed shares or shares in the Company ("Securities") to any person in said
jurisdictions. The information in the press release may not be forwarded or
reproduced in such a manner that contravenes such restrictions or gives cause to
such requirements.
No securities have been or will be registered under the United States Securities
Act of 1933, as amended (the "Securities Act") or the securities legislation of
any state or other jurisdiction in the United States and may not be offered,
subscribed for, exercised, used, pledged, sold, resold, granted, delivered or
otherwise transferred, directly or indirectly, in or into the United States
except pursuant to an applicable exemption from, or in a transaction not subject
to, the registration requirements under the Securities Act and in compliance
with the securities legislation in the relevant state or any other jurisdiction
of the United States.
Within the European Economic Area ("EEA"), no public offering of Securities is
made in other countries than Sweden or Norway. In other member states of the EU,
such an offering of Securities may only be made in accordance with the
Prospectus Regulation (EU) 2017/1129 (the "Prospectus Regulation"). In other
member states of the EEA which have implemented the Prospectus Regulation in its
national legislation, any offer of Securities may only be made in accordance
with an applicable exemption in the Prospectus Regulation and/or in accordance
with an applicable exemption under a relevant national implementation measure.
In the United Kingdom, this document and any other materials in relation to the
securities described herein is only being distributed to, and is only directed
at, and any investment or investment activity to which this document relates is
available only to, and will be engaged in only with, "qualified investors" who
are (i) persons having professional experience in matters relating to
investments who fall within the definition of "investment professionals" in
Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (the "Order"); or (ii) high net worth entities falling
within Article 49(2)(a) to (d) of the Order (all such persons together being
referred to as "relevant persons"). In the United Kingdom, any investment or
investment activity to which this communication relates is available only to,
and will be engaged in only with, relevant persons. Persons who are not relevant
persons should not take any action on the basis of this press release and should
not act or rely on it.
Forward-looking statements
This press release contains forward-looking statements that reflect the
Company's intentions, beliefs, or current expectations about and targets for the
Company's future results of operations, financial condition, liquidity,
performance, prospects, anticipated growth, strategies and opportunities and the
markets in which the Company's operates. Forward-looking statements are
statements that are not historical facts and may be identified by words such as
"believe", "expect", "anticipate", "intend", "may", "plan", "estimate", "will",
"should", "could", "aim" or "might", or, in each case, their negative, or
similar expressions. The forward-looking statements in this press release are
based upon various assumptions, many of which are based, in turn, upon further
assumptions. Although the Company believes that the expectations reflected in
these forward-looking statements are reasonable, it can give no assurances that
they will materialize or prove to be correct. Because these statements are based
on assumptions or estimates and are subject to risks and uncertainties, the
actual results or outcome could differ materially from those set out in the
forward-looking statements as a result of many factors. Such risks,
uncertainties, contingencies and other important factors could cause actual
events to differ materially from the expectations expressed or implied in this
release by such forward-looking statements. The Company does not guarantee that
the assumptions underlying the forward-looking statements in this press release
are free from errors and readers of this press release should not place undue
reliance on the forward-looking statements in this press release. The
information, opinions and forward-looking statements that are expressly or
implicitly contained herein speak only as of its date and are subject to change
without notice. Neither the Company nor anyone else undertake to review, update,
confirm or to release publicly any revisions to any forward-looking statements
to reflect events that occur or circumstances that arise in relation to the
content of this press release.
FDI
The Company assesses that it conducts a business of strategic interest under the
Act (2023:560) on the Review of Foreign Direct Investments (the "FDI Act"). In
accordance with the FDI Act, the Company must inform potential investors that
its operations may fall within the scope of the regulation and that the
investment may be subject to a notification requirement. If an investment is
subject to notification, it must be reported to the Inspectorate of Strategic
Products (ISP) before being completed. An investment may be subject to
notification if the investor, any entity within its ownership structure, or any
party on whose behalf the investor is acting, following the completion of the
investment, holds voting rights corresponding to or exceeding any of the
thresholds of 10, 20, 30, 50, 65, or 90 percent of the total number of votes in
the Company. The investor may be subject to an administrative sanction fee if a
notifiable investment is carried out before ISP has either: i) decided to take
no action on the notification, or ii) approved the investment. Each shareholder
should consult an independent legal advisor regarding the potential
applicability of the FDI Act in relation to the Rights Issue for the individual
shareholder.
Information to distributors
Solely for the purposes of the product governance requirements contained within:
(a) EU Directive 2014/65/EU on markets in financial instruments, as amended
("MiFID II"); (b) Articles 9 and 10 of Commission Delegated Directive (EU)
2017/593 supplementing MiFID II; and (c) local implementing measures (together,
the "MiFID II Product Governance Requirements"), and disclaiming all and any
liability, whether arising in tort, contract or otherwise, which any
"manufacturer" (for the purposes of the MiFID II Product Governance
Requirements) may otherwise have with respect thereto, the shares in the Company
have been subject to a product approval process, which has determined that such
shares are: (i) compatible with an end target market of retail investors and
investors who meet the criteria of professional clients and eligible
counterparties, each as defined in MiFID II; and (ii) eligible for distribution
through all distribution channels as are permitted by MiFID II (the "Target
Market Assessment"). Notwithstanding the Target Market Assessment, Distributors
should note that: the price of the shares in the Company may decline and
investors could lose all or part of their investment; the shares in the Company
offer no guaranteed income and no capital protection; and an investment in the
shares in the Company is compatible only with investors who do not need a
guaranteed income or capital protection, who (either alone or in conjunction
with an appropriate financial or other adviser) are capable of evaluating the
merits and risks of such an investment and who have sufficient resources to be
able to bear any losses that may result therefrom. The Target Market Assessment
is without prejudice to the requirements of any contractual, legal or regulatory
selling restrictions in relation to the new share issue. Furthermore, it is
noted that, notwithstanding the Target Market Assessment, SB1 Markets will only
procure investors who meet the criteria of professional clients and eligible
counterparties.
For the avoidance of doubt, the Target Market Assessment does not constitute:
(a) an assessment of suitability or appropriateness for the purposes of MiFID
II; or (b) a recommendation to any investor or group of investors to invest in,
or purchase, or take any other action whatsoever with respect to the shares in
the Company.
Each distributor is responsible for undertaking its own target market assessment
in respect of the shares in the Company and determining appropriate distribution
channels.
Have a question? We'll get back to you promptly.